MELBOURNE, Australia and KING OF PRUSSIA, Pa., Oct. 20, 2020 /PRNewswire/ -- In its annual R&D briefing to investors today, CSL Limited (ASX:CSL; USOTC:CSLLY) demonstrated how the company is advancing a novel research portfolio across four strategic scientific platforms (Plasma Fractionation, Recombinant Technology, Cell and Gene Therapy, Adjuvanted Cell and Egg-based Vaccines) across six therapeutic areas (Immunology, Hematology, Respiratory, Cardiovascular and Metabolic, Transplant, Influenza Vaccines) and two businesses (CSL Behring and Seqirus) to help patients lead full lives, protect public health and drive future business growth. It's this scientific capability and diverse portfolio that positioned the company to quickly respond to the COVID-19 public health crisis.

"CSL's acumen in vaccines, monoclonal antibodies, recombinant technologies, manufacturing capabilities and external partnerships, along with a therapeutic area focus and insight that includes Immunology and Respiratory, has supported the growth and progress of our pipeline and has also enabled us to respond quickly to the need for potential solutions in the world's fight against COVID-19," said Bill Mezzanotte, MD, MPH,Executive Vice President, Head of Research and Development and Chief Medical Officer. "Right across the spectrum of infection and disease, CSL has taken on projects we think make sense both scientifically and that fit our capabilities."

The company's efforts in the fight against COVID-19 include:

"The same collaborative mindset with which CSL has responded to the COVID-19 pandemic is also reflected in how we are advancing our pipeline," said Andrew Nash, PhD, Senior Vice President, Head of Research and Chief Scientific Officer. "Across therapeutic areas, strategic platforms and geographies we continue to grow our footprint and capabilities so that we can deliver a significant benefit to patients around the world."

Other advancements in CSL's R&D pipeline in the last year include:

Setting the pace in Plasma Product development:CSL is continuously improving current plasma fractionation processes and developing new therapeutic options, which has shown major relevance in the fight against COVID-19 and is also evident in other therapeutic areas. For example:

Advancing its Cell and Gene Therapy research by:

Building momentum in Recombinant Technology:CSL has established a highly differentiated preclinical and clinical stage pipeline of recombinant proteins and monoclonal antibodies from its proficiency in protein biology and innate cell immunity. In addition to using this technology against COVID-19, the company is studying:

About CSL CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visitwww.csl.com.

SOURCE CSL

http://www.csl.com

Read more here:
CSL's Broad Response to COVID-19 and Advancements across the Company's Strategic Scientific Platforms are the Focus of Annual R&D Day - PRNewswire